A transgenic approach to study argininosuccinate synthetase gene expression
© Shiue et al.; licensee BioMed Central Ltd. 2014
Received: 11 March 2014
Accepted: 21 April 2014
Published: 13 May 2014
Argininosuccinate synthetase (ASS) participates in urea, nitric oxide and arginine production. Besides transcriptional regulation, a post-transcriptional regulation affecting nuclear precursor RNA stability has been reported. To study whether such post-transcriptional regulation underlines particular temporal and spatial ASS expression, and to investigate how human ASS gene behaves in a mouse background, a transgenic mouse system using a modified bacterial artificial chromosome carrying the human ASS gene tagged with EGFP was employed.
Two lines of ASS-EGFP transgenic mice were generated: one with EGFP under transcriptional control similar to that of the endogenous ASS gene, another with EGFP under both transcriptional and post-transcriptional regulation as that of the endogenous ASS mRNA. EGFP expression in the liver, the organ for urea production, and in the intestine and kidney that are responsible for arginine biosynthesis, was examined. Organs taken from embryos E14.5 stage to young adult were examined under a fluorescence microscope either directly or after cryosectioning. The levels of EGFP and endogenous mouse Ass mRNAs were also quantified by S1 nuclease mapping. EGFP fluorescence and EGFP mRNA levels in both the liver and kidney were found to increase progressively from embryonic stage toward birth. In contrast, EGFP expression in the intestine was higher in neonates and started to decline at about 3 weeks after birth. Comparison between the EGFP profiles of the two transgenic lines indicated the developmental and tissue-specific regulation was mainly controlled at the transcriptional level. The ASS transgene was of human origin. EGFP expression in the liver followed essentially the mouse Ass pattern as evidenced by zonation distribution of fluorescence and the level of EGFP mRNA at birth. However, in the small intestine, Ass mRNA level declined sharply at 3 week of age, and yet substantial EGFP mRNA was still detectable at this stage. Thus, the time course of EGFP expression in the transgenic mice resembled that of the human ASS gene.
We demonstrate that the transgenic mouse system reported here has the merit of sensitivity and direct visualization advantage, and is ideal for annotating temporal and spatial expression profiles and the regulation mode of the ASS gene.
Argininosuccinate synthetase (ASS; EC 220.127.116.11) is an enzyme that functions in the catalysis of the conversion of citrulline and aspartate to argininosuccinate, which is further converted to arginine by argininosuccinate lyase [1, 2]. ASS catalyzes the rate-limiting step in arginine biosynthesis. Arginine plays a role in the synthesis of urea, nitric oxide (NO), polyamines, proline, glutamate, creatine and agmatine . Thus, ASS participates in fine-tuning production of NO and others to maintain cellular homeostasis in response to cellular and environmental stimuli. Conceivably, ASS, one of the key enzymes involving in arginine metabolism, is subjected to various mechanisms of regulation in both physiological and disease states.
Hormones, such as glucocorticoid, glucagon and insulin, are major regulators of the expression of urea cycle enzymes in the liver [1, 2]. We have previously identified that the cAMP response element (CRE) located at about 10 kb upstream of the transcription start site of the human ASS gene is most likely the target site of the CRE-binding protein (CREB) to mediate glucagon action . However, the mechanism by which glucocorticoid and insulin act on ASS expression remains unknown. On the other hand, ASS expression in non-hepatic cells were shown to be induced by interleukin-1β through NF-κB activation acting at a putative NF-κB binding site at the ASS promoter . Moreover, the proximal promoter of the ASS gene was shown to contain an E-box recognized by c-Myc and HIF-1α, and a GC-box targeted by Sp4 where ASS expression involves interactions between the positive transcriptional factors c-Myc and Sp4 and the negative factor HIF-1α . In addition to regulation at transcription initiation, we have also identified a novel post-transcriptional event affecting ASS nuclear precursor RNA stability in the canavanine-resistant variants of a human squamous cell carcinoma line, RPMI 2650 . These variants express 200-fold increased levels of ASS mRNA as compared to the parental cells . The canavanine-resistant variants have increased ASS activities, and are presumably resistant to canavanine because of increased conversion of citrulline to arginine. The post-transcriptional regulation identified in the canavanine-resistant variants may have physiological relevance since it has the advantage of being faster than transcriptional regulation. One would image that under particular circumstances such as inflammation, cells may employ such a mode of regulation to produce higher levels of ASS mRNA to meet the need for NO production. It is worth noting that similar canavanine-resistant cells have been isolated from lymphoblasts .
To obtain the temporal and spatial expression profiles of ASS transgene, major efforts in this study are to establish the developmental expression pattern of ASS-EGFP in the liver, the organ for urea production, and in the intestine and kidney where arginine biosynthesis occurs. By comparing the expression patterns between Tg(ASS-Ex3-EGFP) that are carrying the transcription reporter and Tg(ASS-Ex16-EGFP) that are carrying the transcription/post-transcription couple reporter, we aim to deduce at which level the expression control acts during development. Moreover, the ASS transgene is of human origin. It would be of interest to know how a human gene behaved in the mouse genetic background.
Mice were housed in a specific pathogen-free (SPF) area of the animal room in the Taipei Veterans General Hospital and were maintained according to protocols approved by the Animal Care and Use Committee of Taipei Veterans General Hospital. The male transgenic mice of the FVB/N strain carrying the ASS-EGFP transgene, i.e., Tg(ASS-Ex3-EGFP) or Tg(ASS-Ex16-EGFP), were mated with wild-type FVB/N female where parturition occurred on day 17.5 or 18.5 after conception. Progenies carrying EGFP transgene were identified by visualization of fluorescence of two-week old littermates by a portable fluorescence detection system. The transgenic mouse lines Tg(ASS-Ex3-EGFP)Tsu and Tg(ASS-Ex16-EGFP)Tsu have been deposited in National Laboratory Animal Center, Taiwan, and are available for researchers on requests.
Histological study was performed following standard protocols . In brief, mice were sacrificed by anesthetized with CO2 and tissue collected was fixed in 4% buffered paraformaldehyde. For frozen section, after dehydration in graded sucrose solution, tissue was embedded in OCT (Optimal Cutting Temperature) compound (Tissue Tec, Sakara, Torrance, CA). Serial sections were performed with Leica cryostat (Leica Biosystems, Wetzlar, Germany) and mounted onto slides to examine EGFP expression by a fluorescence microscope. Slides were counterstained with DAPI (4′,6-diamidino-2-phenylindole) (Roche Applied Science, Indianapolis, IN). For immunohistochemical studies, tissues fixed in buffered paraformaldehyde and embedded in paraffin were deparaffinized, hydrated in graded ethanol, and heated in 10 mM sodium citrate (pH 6.0) plus 0.1% NP-40 by microwave oven to retrieve the antigens. The remaining activity of endogenous peroxidase activity was quenched with hydrogen peroxide. After blocking, the slides were incubated with a primary antibody of GFP (1:100 dilution, anti-GFP, rabbit polyclonal antibody) (Chemicon, Billerica, MA) or 1:100 dilution of a mouse monoclonal anti-ASS antibody (BD Biosciences, San Jose, CA) overnight at 4°C. Subsequently, the slides were incubated with the biotinylated secondary antibody and streptavidin conjugated-HRP (horseradish peroxidase). The HRP was then visualized by the application of substrate chromogen DAB (diaminobenzidine) (Dako, Glostrup, Denmark) to give brown color where the slides were counterstained with hematoxylin.
RNA isolation and S1 nuclease mapping analysis
For total RNA isolation, tissue was first grinded to powder cooled in liquid nitrogen. The frozen powder was transferred to a MagNA Lyser tube (Roche Applied Science, Indianapolis, IN) filled with 1 ml TRIzol (Invitrogen, Carlsbad, CA) and homogenized immediately by MagNA Lyser homogenizer (Roche Applied Science, Indianapolis, IN). The supernatant was used in RNA isolation following manufacturer’s instructions. For S1 nuclease mapping, appropriate restriction enzyme-digested DNA fragment was labeled at the 5’-end with [γ-32P] ATP and T4 polynucleotide kinase . The labeled DNA probe was hybridized to total RNAs prepared from the mouse tissues. The DNA-RNA hybrids that resisted to S1 nuclease digestion were electrophoresed through a 4% polyacrylamide gel containing 7 M urea. Gel was dried and analyzed either by autoradiography or by a phosphorimager (Molecular Dynamics, Sunnyvale, CA).
Results and discussion
ASS-EGFP expression during liver development
Zonation of metabolic pathways is believed to be a mechanism leading to efficient use of precursor pools and energy in an organism . In the rodent, urea cycle enzymes in the liver show zonation distribution, i.e., they are present predominantly in the periportal hepatocytes and declining gradually toward the pericentral hepatocytes. Such a distribution pattern occurs not only at the protein level but also in the mRNAs of these enzymes . To study whether zonation can be visualized by EGFP fluorescence, frozen sections of the liver were examined. Similar EGFP zonation pattern could clearly be seen between transgenic lines carrying the transcription reporter, i.e., 3G and 3J, and the transcription/post-transcription couple reporter, i.e., 16E and 16 F (Figure 2B). In the rodent, Ass RNA zonation has been shown to appear 2 days before birth . In agreement, zonation gradually became apparent at E17.5 and E18.5 (Figure 2C, 3J line) where near-homogeneous EGFP fluorescence distribution was found at E14.5 and E15.5 stages (Figure 2C, 3G line). However, human ASS has been reported to be present in all hepatocytes with no marked zonation . The ASS-EGFP transgene in this study is of human origin, and yet EGFP expression manifested zonation pattern similar to that of the rodent Ass. Apparently, establishment of zonation pattern is made at transcription initiation and such regulation may be influenced by cellular environment. Thus, human ASS gene when in the rodent background follows the expression pattern of the rodent.
ASS-EGFP expression during kidney development
ASS-EGFP expression during intestine development
Expression profiling of EGFP and Ass mRNAs in the liver, kidney and intestine by S1 nuclease mapping
Analysis of liver RNA from fetal E14.5 stage to 4 week after birth, EGFP mRNA level was found to increase progressively during the development (Figure 5B). Significant variations in EGFP mRNA abundances among mouse littermates were found. Such variations were also noted when EGFP fluorescence of a particular organ was examined directly (Figures 2A, 3, 4A). To study whether EGFP expression profile differs between Tg(ASS-Ex3-EGFP) Tsu and Tg(ASS-Ex16-EGFP) Tsu lines during liver development, relative abundances of EGFP mRNAs was determined (Figure 5C, upper panel). The EGFP mRNA levels among the transgenic lines were found to be approximately reflecting their transgene copy numbers (Figure 5C, upper panel), suggesting that developmental ASS expression in the liver is mainly controlled at transcription initiation. If the novel post-transcriptional regulation affecting ASS nuclear precursor RNA stability similar to that in canavanine-resistant variants occurred in the Tg(ASS-Ex16-EGFP) Tsu line , one would expect the EGFP mRNA level in the Tg(ASS-Ex16-EGFP) Tsu line to increase by one to two orders of magnitude from current levels. However, whether any subtle post-transcriptional regulation on ASS mRNA has taken place would require further studies. Nevertheless, both the 1.7- and 2.7-kb ASS mRNA species are highly stable with a half-life of approximately 15–20 h . It is noted that among the organs examined, EGFP fluorescence in the Tg(ASS-Ex16-EGFP) Tsu line was generally weaker yet considerably high levels of EGFP mRNA could be detected. It is likely that EGFP in the Tg(ASS-Ex16-EGFP) Tsu line, which is the downstream cistron, is translated by IRES mechanism which may be less efficient comparing to cap-dependent translation of EGFP in the Tg(ASS-Ex3-EGFP) Tsu line.
In rodents, Ass gene expression, assayed by RNA or by activities, is reported to increase progressively towards birth reaching about 50% of adult liver value . In contrast, in human fetuses, ASS activities reached 90% of the adult value at 36 weeks of gestation . Our study showed that the EGFP mRNA abundances at birth were less than 40% of the adult values (Figure 5C, upper panel). Thus, EGFP mRNA profile during liver development is similar to that of mouse Ass mRNA, suggesting that the human ASS gene in the mouse background follows the mouse Ass developmental pattern. Similar conclusion has been obtained as evidenced by liver zonation distribution of EGFP fluorescence (Figure 2B). Thus, the human ASS gene in the mouse genetic background follows mouse Ass developmental pattern. This is not surprising since the ASS gene during liver development is known to subject to both hormonal and nutritional regulation [1, 2]. Therefore, cellular environment plays important role in ASS expression. The results indicate that the cis-elements required for ASS expression during liver development are similar between the human and the mouse, and the ASS-EGFP transgene carries sufficient elements to execute such regulation.
To study whether the transgene expression may affect endogenous Ass gene expression, levels of Ass mRNA were compared between the 3G and 3J lines of Tg(ASS-Ex3-EGFP) Tsu, which carry 30 and 2 copies of transgene, respectively. Indeed, a significantly higher level of EGFP mRNA was found in the 3G line compared to that of the 3J line, yet comparable abundance of Ass mRNA was detected among the transgenic lines 3G and 3J and that of the wild-type mouse (Figure 5C, lower panel). Similar results were found in the analysis of the Tg(ASS-Ex16-EGFP) Tsu line (Figure 5C, lower panel 16E and 16 F). Therefore, even in the presence of high copies of the transgene, no apparent sequestration of transcription factors to affect endogenous gene expression occurs.
Approach similar to that of the liver was taken to study EGFP mRNA expression during kidney development (Figure 6). However, due to limit amounts of sample in fetal E14.5 and E15.5 stages, analysis started at fetus E16.5 stage. Representative images of RNA analysis by S1 nuclease mapping are shown in Figure 6A. The EGFP expression profile was similar between the Tg(ASS-Ex3-EGFP) Tsu and Tg(ASS-Ex16-EGFP) Tsu lines (Figure 6B, upper panel), suggesting ASS expression during kidney development is controlled mainly at the transcription level. By comparing Ass mRNA levels between wild-type and transgenic lines, one concludes that expression of the transgene does not interfere with expression of the endogenous Ass gene during kidney development in the mouse (Figure 6B, lower panel).
To study EGFP mRNA expression profiles in the intestine, RNA of the digestion system including stomach to rectum at the fetal stage was isolated. After birth, only RNA from the small intestine was analyzed. Because EGFP fluorescence intensity was found to vary among different sections of the small intestine (data not shown), to avoid complication, the entire small intestine was collected and used for RNA isolation. In this study, we again showed that EGFP mRNA abundance during intestine development is mainly controlled at the transcription initiation and expression of the transgene did not interfere with endogenous Ass expression (Figure 7). Interestingly, although there were similarities between the expression profiles of EGFP and Ass mRNAs, some differences did exist (Figure 7B). For example, in contrast to EGFP mRNA which showed smooth increases in its abundance perinatally, a rather sharp increase in Ass mRNA abundance at E17.5 stage was observed (Figure 7B). Moreover, the Ass mRNA levels declined sharply at 3 weeks of age, but substantial EGFP mRNA could be detected at this stage in both Tg(ASS-Ex3-EGFP) Tsu or Tg(ASS-Ex16-EGFP) Tsu lines (Figure 7B). In this regard, a previous study of arginine-metabolizing enzymes in the developing rat small intestine found that mRNA levels of all genes in arginine metabolism were highest during the suckling period where Ass mRNAs declined to hardly detectable levels in the second postnatal week . On the other hand, in piglets, net synthesis of arginine declines more gradually in the small intestine and is still present at 7 weeks of age . The perinatal human intestine resembles that of piglets in that ASS activities are highest during the suckling period and declines to low levels around weaning and then rises again . Thus, in contrast to mouse Ass mRNA that disappears completely at 3 week, the EGFP mRNA expression profile of the transgenic mice resembles human ASS in that substantial levels of EGFP mRNA could still be detected at 8 weeks of age (Figure 7). Apparently, ASS gene in humans and pigs has specific cis-element(s) which differ from those of the rodent in regulating ASS expression in the small intestine. By comparison of the upstream ASS gene sequences in human, pig and mouse, such cis-element(s) may be deduced.
Using transgenic mouse system, we show in this study that developmental- and tissue-specific ASS expression of liver, kidney and intestine is mainly controlled at transcription initiation. This is not surprising since transcription initiation, the first step of gene regulation, is the most important mechanism to determine whether or not genes are expressed and then, how much of encoded mRNAs are produced. On the other hand, the novel post-transcriptional regulation identified in canavanine-resistant variants may be so genetically programmed in particular cell types to meet immediately the demand for high ASS activity. Our preliminary study indicates such regulation may occur during mouse fetal brain development (T Su, unpublished data). The region of the brain involved is currently under characterization. On the other hand, the ASS gene in this transgenic mouse system is of human origin. How would the transcriptional programs of human gene follow in mouse genetic background? In this regard, Wilson et al.,  have initiated an important study by taken a mouse model of Down syndrome in which mouse cells contain a copy of human chromosome 21. They concluded that genetic sequence is largely responsible for directing transcriptional programs in homologous tissues. Others such as interspecies differences in epigenetic machinery, cellular environment, and transcription factors themselves play secondary roles. Our study shows that developmental program of ASS-EGFP transgene in liver is similar to rodent, suggesting genetic elements determining liver development are comparable between human and rodent. Thus, cellular environments play important role in shaping ASS-EGFP transcriptional program during liver development. On the other hand, the time course of EGFP expression in small intestine resembles that of human ASS gene, suggesting the presence of particular genetic sequence(s) in ASS gene that dictates human intestine development.
We demonstrate that this transgenic mouse system is ideal for annotation of temporal and spatial expression profiles of the ASS gene. In particular, the Tg(ASS-Ex3-EGFP) 3GTsu line, containing 30 copies of the transgene, generates strong EGFP signals, and is, thus, useful in revealing weak expression. It is conceivable that a comprehensive knowledge of cell types expressing ASS may provide insights into the function. Such knowledge should facilitate investigation of the role of ASS in conditions of physiological and disease states, especially when ASS mRNA or protein are found not to be expressed in many tumours including hepatocellular carcinoma (HCC), melanoma, some mesotheliomas, renal cell cancers, sarcomas and lymphomas . As a result, arginine deprivation employing the pegylated form of arginine deiminase (ADI-PEG20) as a targeted therapy is currently in clinical trials for patients with HCC and melanoma . In this respect, feature of down-regulated expression of ASS in HCC has been recaptured in our ASS-EGFP transgenic mouse model (manuscript in preparation). Thus, questions such as physiological or pathophysiological response of ASS expression stimulated by a variety of signals may be tackled using this system.
We thank Kong-Bung Choo for critical reading and editing of the manuscript, Chun-Ming Chen, Ting-Fen Tsai and Hsian-guey Hsieh for technical support. This work was supported by grants NSC 99-2320-B-075-001 from the National Science Council and by grants V98C1-188 and V100C-107 from the Taipei Veterans General Hospital, Taiwan.
- Husson A, Brasse-Lagnel C, Fairand A, Renouf S, Lavoinne A: Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur J Biochem. 2003, 270: 1887-1899. 10.1046/j.1432-1033.2003.03559.x.View ArticlePubMedGoogle Scholar
- Haines RJ, Pendleton LC, Eichler DC: Argininosuccinate synthase: at the center of arginine metabolism. Int J Biochem Mol Biol. 2011, 2: 8-23.PubMed CentralPubMedGoogle Scholar
- Morris SM: Arginine: beyond protein. Am J Clin Nutr. 2006, 83: 508S-512S.PubMedGoogle Scholar
- Guei TR, Liu MC, Yang CP, Su TS: Liver-specific cAMP responsive element in the human argininosuccinate synthetase gene. Biochem Biophys Res Commun. 2008, 377: 257-261. 10.1016/j.bbrc.2008.09.118.View ArticlePubMedGoogle Scholar
- Brasse-Lagnel C, Lavoinne A, Loeber D, Fairand A, Bôle-Feysot C, Deniel N, Husson A: Glutamine and interleukin-1β interact at the level of Sp1 and nuclear factor-κB to regulate argininosuccinate synthetase gene expression. FEBS J. 2007, 274: 5250-5262. 10.1111/j.1742-4658.2007.06047.x.View ArticlePubMedGoogle Scholar
- Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT: Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1α/Sp4. Mol Cancer Ther. 2009, 8: 3223-3233. 10.1158/1535-7163.MCT-09-0794.PubMed CentralView ArticlePubMedGoogle Scholar
- Tsai TF, Su TS: A nuclear post-transcriptional event responsible for overproduction of argininosuccinate synthetase in a canavanine-resistant variant of a human epithelial cell line. Eur J Biochem. 1995, 229: 233-238. 10.1111/j.1432-1033.1995.tb20460.x.View ArticlePubMedGoogle Scholar
- Su TS, Beaudet AL, O’Brien WE: Increased translatable messenger ribonucleic acid for argininosuccinate synthetase in canavanine-resistant human cells. Biochemistry. 1981, 20: 2956-2960. 10.1021/bi00513a037.View ArticlePubMedGoogle Scholar
- Jacoby LB: Canavanine-resistant variants of human lymphoblasts. Somat Cell Genet. 1978, 4: 221-231. 10.1007/BF01538986.View ArticlePubMedGoogle Scholar
- Larsson LI: Immunocytochemistry: Theory and Practice. 1988, Boca Raton, Florida: CRC Press IncGoogle Scholar
- Sambrook J, Russell DW: Molecular Cloning: A Laboratory Manual. 2001, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 3Google Scholar
- Bourgeois P, Harlin JC, Renouf S, Goutal I, Fairand A, Husson A: Regulation of argininosuccinate synthetase mRNA level in rat foetal hepatocytes. Eur J Biochem. 1997, 249: 669-674. 10.1111/j.1432-1033.1997.t01-1-00669.x.View ArticlePubMedGoogle Scholar
- Hutmacher DW, Dokland T, Ng MML: Techniques in Microscopy for Biomedical Applications. 2006, Singapore: World Scientific Pub Co Inc, 1Google Scholar
- Dingemanse MA, De Jonge WJ, De Boer PAJ, Mori M, Lamers WH, Moorman AF: Development of the ornithine cycle in rat liver: Zonation of a metabolic pathway. Hepatology. 1996, 24: 407-411. 10.1002/hep.510240219.View ArticlePubMedGoogle Scholar
- Saheki T, Yagi Y, Sase M, Nakano K, Sato E: Immunohistochemical localization of argininosuccinate synthetase in the liver of control and citrullinemic patients. Biomed Res Tokyo. 1983, 4: 235-238.Google Scholar
- Morris SM, Sweeney WE, Kepka DM, O’Brien WE, Avner ED: Localization of arginine biosynthetic enzymes in renal proximal tubules and abundance of mRNA during development. Pediatr Res. 1991, 29: 151-154. 10.1203/00006450-199102000-00010.View ArticlePubMedGoogle Scholar
- Kriz W, Koepsell H: The structural organization of the mouse kidney. Anat Embryol. 1974, 144: 137-163.Google Scholar
- Georgas K, Rumballe B, Wilkinson L, Chiu HS, Lesieur E, Gilbert T, Little MH: Use of dual section mRNA in situ hybridisation/immunohistochemistry to clarify gene expression patterns during the early stages of nephron development in the embryo and in the mature nephron of the adult mouse kidney. Histochem Cell Biol. 2008, 130: 927-942. 10.1007/s00418-008-0454-3.View ArticlePubMedGoogle Scholar
- Morris SM: Regulation of enzymes of the urea cycle and arginine metabolism. Annu Rev Nutr. 2002, 22: 87-105. 10.1146/annurev.nutr.22.110801.140547.View ArticlePubMedGoogle Scholar
- De Jonge WJ, Dingemanse MA, De Boer PAJ, Lamers WH, Moorman AFM: Arginine-metabolizing enzymes in the developing rat small intestine. Pediatr Res. 1998, 43: 442-451. 10.1203/00006450-199804000-00002.View ArticlePubMedGoogle Scholar
- Tsai TF: Regulation of Human Argininosuccinate Synthetase Gene Expression. PhD Thesis. 1995, Taiwan: National Yang-Ming University, Institute of Microbiology & ImmunologyGoogle Scholar
- Ali Baig MM, Habibullah CM, Swamy M, Hassan SI, Zaman TU, Ayesha Q, Devi BG: Studies on urea cycle enzyme levels in the human fetal liver at different gestational ages. Pediatr Res. 1992, 31: 143-145. 10.1203/00006450-199202000-00010.View ArticleGoogle Scholar
- Stoll B, Henry J, Reeds PJ, Yu H, Jahoor F, Burrin DG: Catabolism dominates the first-pass intestinal metabolism of dietary essential amino acids in milk protein-fed piglets. J Nutr. 1998, 128: 606-614.PubMedGoogle Scholar
- Köhler ES, Sankaranarayanan S, van Ginneken CJ, van Dijk P, Vermeulen JL, Ruijter JM, Lamers WH, Bruder E: The human neonatal small intestine has the potential for arginine synthesis; developmental changes in the expression of arginine-synthesizing and -catabolizing enzymes. BMC Dev Biol. 2008, 8: 107-122. 10.1186/1471-213X-8-107.PubMed CentralView ArticlePubMedGoogle Scholar
- Wilson MD, Barbosa-Morais NL, Schmidt D, Conboy CM, Vanes L, Tybulewicz VLJ, Fisher EMC, Tavaré S, Odom DT: Species-specific transcription in mice carrying human chromosome 21. Science. 2008, 322: 434-438. 10.1126/science.1160930.PubMed CentralView ArticlePubMedGoogle Scholar
- Phillips MM, Sheaff MT, Szlosarek PW: Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat. 2013, 45: 251-262. 10.4143/crt.2013.45.4.251.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.